Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

News SummaryMost relevantAll newsSector newsTweets

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 10:20pm CET

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
[email protected]

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
11:51a HALOZYME THERAPEUTICS : To Participate In Upcoming Healthcare Conferences
11/16 HALOZYME THERAPEUTICS : To Present Nonclinical Data At SITC 2017 Supporting Comb..
11/15 HALOZYME THERAPEUTICS : To Participate In Upcoming Healthcare Conferences
11/10 HALOZYME THERAPEUTICS : To Present Nonclinical Data At SITC 2017 Supporting Comb..
11/09 HALOZYME THERAPEUTICS : Phase 3 Study Of Subcutanous Daratumumab Initiated Using..
11/08 HALOZYME THERAPEUTICS : beats 3Q profit forecasts
11/07 HALOZYME THERAPEUTICS INC : Results of Operations and Financial Condition (form ..
11/07 HALOZYME THERAPEUTICS : Reports Third Quarter 2017 Results
11/07 HALOZYME THERAPEUTICS, INC. : to Host Earnings Call
11/03 HALOZYME THERAPEUTICS : Phase 3 Study of Subcutanous Daratumumab Initiated Using..
More news
News from SeekingAlpha
11/10 Halozyme Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides
11/09 YOUR DAILY PHARMA SCOOP : Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumb..
11/09 Steer Clear Of AMC - Cramer's Lightning Round (11/8/17)
11/07 Halozyme Therapeutics' (HALO) CEO Dr. Helen Torley on Q3 2017 Results - Earni..
11/07 Halozyme Therapeutics beats by $0.12, beats on revenue